Don't miss SGLT Tools - PowerPoint slide library for SGLT2 inhibitors

UKidney Nephrology News and Insights

UKidney Renal Week 2019 Update Banner

We are pleased to announce our collaboration with ConferenceInsider™ to bring you on-site coverage of ASN Kidney Week 2019 from our nation's capital. We'll bring you the heart of ASN Kidney Week 2019, from November 7 - 11, 2019. This is your direct connection to the most trusted and clinically relevant information about recent advances in the...

UKidney Renal Week 2019 Update Banner

We are pleased to announce our collaboration with ConferenceInsider™ to bring you on-site coverage of ASN Kidney Week 2019 from our nation's capital. We'll bring you the heart of ASN Kidney Week 2019, from November 7 - 11, 2019. This is your direct connection to the most trusted and clinically relevant information about recent advances in the field of nephrology.

We'll continue to post educational session summaries and interviews with key opinion leaders throughout the conference – delivering the latest developments in nephrology medicine and patient care right to your email inbox. We want to hear from you, too. So be sure to share your opinions through our insightful daily polls.

If you’re not signed up already, please subscribe to UKidney to receive daily emails throughout ASN Kidney Week 2019. Each email will directly link to posted session updates. We hope you enjoy this resource!

The UKidney & ConferenceInsider Teams

More
NOV
12
0

Canagliflozin in patients with very low GFR: Protection persists

Excitement for the SGLT2 inhibitor class continued at the 2019 ASN Kidney Week. Evidence continues to accumulate from analyses of the CREDENCE trial which originally showed - for the first time in a randomized controlled study with hard renal outcomes - that patients taking canagliflozin experienced slower decline in their kdiney function and a reduction in the incidence of end-stage renal failure requiring dialysis or kidney transplant. In the CREDENCE study, patients with an estimated eGFR below 30 ml/min were excluded from the trial. However, patients who had a eGFR > 30 ml/min at the time of screening but in whom the eGFR fell below 30 ml/min by the time of randomization were nevertheless included in the study.

Continue reading
NOV
11
0

An open-label extension study to evaluate the efficacy and safety of Roxadustat for the long-term maintenance treatment of anemia in dialysis and non-dialysis patients with CKD

Category: Anemia and Iron Metabolism: Clinical  

Authors: Chao H. Sun MD, FASN; Elizabeth A. Barranco MD; Lona Poole, MD; Meraf Eyassu RN; Cameron S. Liu PhD; Donna L. Kline; Thomas B. Neff; Kin-Hung Peony Yu, MD

Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, stimulates erythropoiesis by increasing erythropoietin, and regulates iron metabolism.

An open-label, extension study originally included 14 subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD) and 1 subject with dialysis-dependent chronic kidney disease (DD-CKD). After enrollment, 2 of the subjects ended up being excluded from analyses – one with NDD-CKA withdrew consent two weeks post-enrollment and one with DD-CKD was excluded.

Continue reading
NOV
11
0

Global Kidney Health Atlas: Why We Need It and How It May Affect CKD Worldwide

Session: Global Challenges of CKD

Sub-session: Global Kidney Health Atlas: Why We Need It and How It May Affect CKD Worldwide

Presenter: David W. Johnson DrMed, MBBS, PhD, FASN

David Johnson25David W. JohnsonDavid W. Johnson, MBBS, led the session of the global challenges of CKD with his presentation on the Global Kidney Health Atlas (GKHA), why a report like this is needed and how it may impact CKD worldwide.

The GKHA gathers “data [from all over the globe] to determine the status of existing resources, structures and organizations available to patients with CKD and AKI”.

Continue reading
NOV
11
0

24-hydroxylase deficiency: comparison with other disorders of vitamin D-mediated hypercalcemia

Category: Bone and Mineral Metabolism

Authors: Sarah M. Azer, Mayo Clinic; Lisa E. Vaughan, MS; Peter Tebben, MD; David J. Sas DO, MPH

This study compared laboratory, imaging, clinical characteristics of patients with suspected or confirmed 24 Hydroxylase (24HD) “to other disorders of vitamin D-mediated hypercalcemia such as, sarcoidosis (S), lymphoma (L), and exogenous vitamin D toxicity (EVT).” Patients with 24 Hydroxylase (24HD) “have clinical and laboratory differences compared to other causes of vitamin D mediated hypercalcemia.” For patients with hypercalcemia who present at a young age, have a positive family history, and have nephrocalcinosis, clinicians should suspect 24HD.

Continue reading
NOV
11
0

Hot off the Press: The Advancing Kidney Health Initiative and More

Session: Hot off the Press: The Advancing Kidney Health Initiative and More

Sub-session: KidneyX: Redesign Dialysis, Patient Innovators Challenge, and Beyond

Presenter: Nick Uehlecke

Nick Uehlecke 2Nick UehleckeDuring one of the final sessions at ASN Kidney Week 2019, doctors and patients tuned in on the latest-breaking developments in public policy, specifically, the focus on the Advancing American Kidney Health Initiative and congressional and regulatory policy changes that are underway.

Continue reading
ukidneyisup